{"id":61983,"date":"2025-10-07T13:02:53","date_gmt":"2025-10-07T11:02:53","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/new-study-in-journal-of-the-national-cancer-institute-finds-cologuard-plus-provides-the-most-life-years-gained-with-the-fewest-colonoscopies\/"},"modified":"2025-10-07T13:02:53","modified_gmt":"2025-10-07T11:02:53","slug":"new-study-in-journal-of-the-national-cancer-institute-finds-cologuard-plus-provides-the-most-life-years-gained-with-the-fewest-colonoscopies","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/new-study-in-journal-of-the-national-cancer-institute-finds-cologuard-plus-provides-the-most-life-years-gained-with-the-fewest-colonoscopies\/","title":{"rendered":"New Study in Journal of the National Cancer Institute Finds Cologuard Plus\u2122 Provides the Most Life-Years Gained with the Fewest Colonoscopies"},"content":{"rendered":"
\n

\nFirst evaluation of benefit-to-burden for new screening options using methodologies adopted by the United States Preventive Services Task Force<\/i><\/p>\n

\nNoninvasive test performance is critical to support patient outcomes and reduce burden on limited colonoscopy capacity<\/i><\/p>\n

MADISON, Wis.–(BUSINESS WIRE)–Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests today announced the publication of \u201cComparing Benefit-to-Burden Ratios of Endorsed and Emerging Colorectal Cancer Screening Strategies\u201d<\/a> in the Journal of the National Cancer Institute<\/i>.1<\/sup> The modeling study found that Cologuard Plus\u2122, a triennial next-generation multitarget stool DNA (mt-sDNA) test, was the only noninvasive screening option shown to be efficient at guideline-recommended intervals and age ranges.1<\/sup><\/p>\n

<\/a>
<\/a><\/p>\n

\nThis study leveraged the validated CRC-AIM microsimulation platform, and the same modeling approach developed by the Cancer Intervention and Surveillance Monitoring Network (CISNET) that was used to inform the United States Preventive Services Task Force\u2019s (USPSTF) 2021 colorectal cancer screening guidelines. It incorporated new clinical data published since that update and was sponsored by Exact Sciences.<\/p>\n

\n\u201cThis analysis provides new insights into how different colorectal cancer screening strategies balance benefit and burden,\u201d said Dr. Derek Ebner, gastroenterologist, Mayo Clinic and first author of the study. \u201cHaving accessible, high-performing noninvasive options for patients encourages screening completion and preserves access to colonoscopy for those who need it most.\u201d<\/p>\n

\nThe USPSTF2<\/sup> defines an \u201cefficient\u201d screening strategy as one that delivers the greatest number of life-years gained for the fewest colonoscopies.2<\/sup> This benefit-to-burden ratio is driven largely by test performance:<\/p>\n